Results 31 to 40 of about 17,623 (143)

Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment

, 2021
Aim: Infections by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae represent a major challenge because of limited treatment strategies. New β-lactam/β-lactamase inhibitor associations may help to deal with this challenge.
Romanelli, Federica, Morea, Anna, Prete, Raffaele Del, Mosca, Adriana, Stolfa, Stefania, Chironna, Maria, Santacroce, Luigi, Ronga, Luigi   +7 more
core   +1 more source

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date

Infection and Drug Resistance, 2023
Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
doaj  

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Microbiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero   +6 more
doaj   +1 more source

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Antibiotics, 2021
The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients.
Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang   +7 more
doaj   +1 more source

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

, 2022
Introduction: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Giamarellos-Bourboulis, E.J., Mouktaroudi, M., Kotsaki, A.   +2 more
core   +1 more source

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source

Potency of Meropenem-Vaborbactam in Lung Surfactant

, 2018
This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several
Debora Rubio-Aparicio, Michael Dudley, Olga Lomovskaya, Jeff Loutit   +3 more
core   +1 more source

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

Journal of Global Antimicrobial Resistance, 2023
: Objectives: Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (
A. Oliva, D. Al Ismail, G. Arcari, MC. Miele, E. Casali, F. Sacco, L. Volpicelli, M. De Angelis, M.T. Mascellino, F. Cancelli, G. Raponi, A. Carattoli, M Venditti   +12 more
doaj   +1 more source

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections

, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and ...
Hung-Jen Tang, Chi-Chung Chen, Chih-Cheng Lai   +2 more
core   +1 more source

Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies

Antimicrobial Agents and Chemotherapy
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp).
Marta Hernández-García, Blanca Pérez-Viso, Marta Nieto-Torres, María García-Castillo, Malkoa Michelena, Luis Martínez-Martínez, Fernando Baquero, Patricia Ruiz-Garbajosa, Rafael Cantón   +8 more
doaj   +1 more source